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Abstract
Introduction: Although nicorandil is prescribed widely, awareness of its potential to cause serious
complications to the gastrointestinal tract mucosa is limited. Whilst nicorandil-induced oral and
anal ulceration is well documented in the literature, nicorandil-induced fistulation is not. This is the
first report in the literature of a single patient demonstrating simultaneous orocutaneous and anal
fistulae during nicorandil therapy. Two separate cases of orocutaneous and anal fistulae associated
nicorandil usage have previously been documented in specialist journals.
Case presentation: A 71-year-old Caucasian man presented with a 3-year history of concurrent
orocutaneous and anal fistulae. He had been exposed to 30 mg twice-daily nicorandil therapy for
4 years. Both fistulae responded poorly to intensive and prolonged conventional treatment but
healed promptly on reduction and eventual withdrawal of nicorandil therapy.
Conclusion: Management of resistant cases of orocutaneous and anal fistulae in patients on high-
dose nicorandil therapy may be impossible without reduction or even withdrawal of nicorandil.
Introduction
Nicorandil was first introduced as an anti-anginaltreat-
ment in Japan over 20 years ago and is widely prescribed
in the UK [1]. As a potassium channel opener with a
nitrate component, nicorandil reduces both preload and
afterload [2], and its use is often employed in the difficult
challenge of managing patients with refractory or unstable
angina pharmacologically. It is recommended as second-
line therapy in reducing the symptoms and signs of
angina pectoris and myocardial ischaemia[3]. Nicorandil
is generally well tolerated with common side effects
including flushing, headache and nausea [4]. However, it
has become increasingly recognised that its usage is also
associated with debilitating ulcer formation. Since the first
French report of nicorandil-induced oral ulcers in 1997
[5], there have been reports of other nicorandil-induced
ulcers, including anal, peri-anal [6,7], vulval and peris-
tomal ulcers [8]. A single case of small and large bowel
ulcers leading to a perforated terminal ileum has also
been described in the literature [9].
We describe a single case involving both orocutaneous
and anal fistulae in a patient on nicorandil. Unlike its
well-known association with ulcer formation, reports of
nicorandil-induced fistulae formation are very rare in the
literature. To our knowledge, only a single paper [8] has
been published describing four cases of fistulating large
bowel disease, one 'letter to the editor' [10] describing a
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case of orocutaneous fistula following nicorandil therapy
and another letter [11] reporting a case of nicorandil-asso-
ciated peri-anal fistula formation.
Many of these case reports appear in specialised cardiol-
ogy, dermatology, surgery and dentistry journals. There-
fore, given the widespread prescribing of nicorandil, this
case report aims to generate increasing awareness of its
serious complications amongst general physicians.
Case presentation
A 71-year-old Caucasian man was admitted to our hospi-
tal under the general medical team in July 2007 with a 15-
month history of recurrent cellulitis over the right maxil-
lary region of his face. There were no obvious aetiological
factors apart from stable tablet-controlled type 2 diabetes
mellitus. Wound swabs for microscopy, culture and sensi-
tivity were repeatedly negative and there was no history of
trauma or underlying dermatological disease. The patient
had suffered from a dental abscess involving the right
upper quadrant molars, but this was noted only 13
months following his initial presentation in 2006; tooth
extractions performed with a view to curing his facial cel-
lulitis had limited effect on this. Multiple courses of
broad-spectrum oral and intravenous antibiotics had
been ineffective in treating the cellulitis. Two computed
tomography (CT) scans of the paranasal sinuses per-
formed in February and July 2007 had ruled out sinusitis
as an underlying cause. The patient had declined to have
a skin biopsy.
Several days after admission, the patient developed an
abscess over the right maxillary region and began com-
plaining of a foul taste in his mouth from the discharging
abscess. It was at this point that a discharging fistula
between the right nasolabial fold and the right buccal sul-
cus was diagnosed clinically. Following reviews by clini-
cians in the areas of dermatology, microbiology, ENT (ear
nose and throat) and maxillofacial surgery, the signifi-
cance of this patient's nicorandil treatment (30 mg twice
daily) initiated 4 years previously, was recognised. His
drug history also included spironolactone, isosorbide
mononitrate, warfarin, gliclazide, bisoprolol, paroxetine
and furosemide. On direct questioning, the patient admit-
ted to having experienced small oral ulcers involving his
tongue 6 months preceding his admission, although he
had not sought medical advice as they had not been par-
ticularly troubling. On this occasion, he had no oral
ulcers.
On discussion with the cardiologists, the patient was put
on a 4-week long tapering regimen of nicorandil resulting
in complete withdrawal of nicorandil therapy. There was
some clinical improvement noted at 2 weeks into this
reducing regime and a month after his nicorandil therapy
had ceased, his fistula had healed and the cellulitis disap-
peared completely for the first time in 15 months.
A retrospective review of his imaging confirmed a fistula
in the right maxillary region on the CT scan performed in
February 2007. The patient had not complained of any
symptoms suggestive of a fistula at this point. However,
retrospective questioning revealed that he had had symp-
toms of a 'foul taste' in his mouth during this time, which
he had initially attributed to the dental abscess.
In addition, investigation of the patient's case notes
revealed that he had had a persistent peri-anal fistula over
a period of 1 year from 2004 to 2005. This low anal fistula
was initially laid open surgically in 2004. However, this
procedure was complicated by poor wound healing and
abscess formation requiring two further surgical proce-
dures over the next year. The fistula finally healed in mid-
2005, corresponding to a coincidental nicorandil dose
reduction from a total daily dose of 60 mg to 30 mg dur-
ing the preceding month.
Discussion
More than 50 cases of nicorandil-induced oral ulcers have
been reported. A prospective study by Marquart-Elbaz et
al. [12] reported a 5% prevalence of oral ulceration in
patients on nicorandil, compared with patients on various
other anti-anginal medications. In contrast, a prescription
event monitoring study assessing 13,260 patients
reported a much lower incidence of 0.4% [13]. The
median onset of ulcer formation following commence-
ment of nicorandil has been found to be 12 months, with
a range of 2-36 months [14]. These ulcers are large (up to
several centimetres is size), persistent, recurring, deep and
painful but healpromptly after withdrawal of nicorandil
[15]. The tongue is often affected, but the ulceration can
also involve the hard palate, buccal and labial mucosa
[14,16]. The lesions have a consistent appearance from
patient to patient, and were initially described as 'aph-
thous ulcers'. However, a recent study in 2003 involving
60 dermatologists reported the ulcers as 'non-aphthous'
in nature [17] (Table 1).
Biopsies of these ulcers show non-specific features of
ulceration [15], that is, granulation tissue associated with
acute inflammation. These ulcers show a poor response to
topical steroids [14,15]. Transient healing is seen in some
cases treated with colchicine or thalidomide but the ulcers
Table 1: A comparison of aphthous and non-aphthous ulcers
Aphthous ulcer Non-aphthous ulcer
Often has yellow base
Erythematous halo
Punched out appearance
No surrounding erythematous haloJournal of Medical Case Reports 2009, 3:119 http://www.jmedicalcasereports.com/content/3/1/119
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relapse rapidly once treatment is stopped [14]. The defin-
itive treatment is withdrawal of nicorandil, which must be
done with caution, instituting a gradually tapering regi-
men and starting another anti-anginal if necessary, to
avoid exacerbation of anginal symptoms. The Medicines
and Healthcare Products Regulatory Agency advises that
nicorandil withdrawal be carried out only under the
supervision of a cardiologist [18]. Patients often describe
a dramatic decrease in pain within 2 weeks of withdrawal,
and healing in around 4 weeks, mostly without scarring
[16].
A single case of orocutaneous fistula has been described in
the form of a 'letter to the editor' in 2005 [10]. The patient
described had a full thickness defect of his left cheek and
a deeply ulcerated area in the floor of his mouth. Nicoran-
dil was stopped and nasogastric feeding was commenced
to aid healing inside the mouth. The mouth ulcer healed
in 6 weeks but a facial flap was required to close the fis-
tula. The patient recovered well with no recurrence of the
oral ulcer.
These ulcers and fistulae are distressing for patients with
resulting dysphagia, weight loss and occasionally depres-
sion [12]. In cases where the diagnosis is in doubt, biopsy
should be performed to rule out other aetiologies, espe-
cially malignancy. Super-infection caused by bacteria or
fungi may also need to be excluded. The significance of
this was demonstrated in a recent case report of a patient
with nicorandil-induced oral ulceration and cervicofacial
actinomycosis [19].
The phenomenon of anal ulceration was first recognised
by Watson et al. [6] and more cases have been reported
since. Patients often complain of anal pain, pain on defe-
cation or bleeding per rectum and can present with acute
anal fissures or suspicious-looking anal ulcers. These
ulcers are, again, deep punched out cavities with well-cir-
cumscribed edges. Histological examination of these areas
shows non-specific inflammation with no evidence of
malignancy [6,7]. Similarly to the oral ulcers, the anal and
peri-anal ulcers demonstrate dramatic improvement fol-
lowing withdrawal of nicorandil in terms of pain and
appearance [6-8]. However, in contrast to oral ulcers,
complete healing of ulcers in the gastrointestinal tract
takes longer, ranging from 4 to 10 months following nic-
orandil withdrawal in one study [8].
Kamath et al. [11] described a single case of a patient pre-
senting with a low peri-anal fistula that failed to respond
to routine surgical management. The fistula was surgically
laid open on two occasions over an 18-month period.
However, the postoperative healing was complicated both
times by development of a large, non-healing ulcer. There-
fore, the patient underwent an abdominoperineal exci-
sion with defunctioning colostomy. Despite this, the peri-
anal ulcer persisted and new ulcers began to form on the
skin of the scrotum and groin. Six weeks after stopping his
20 mg twice daily dose of nicorandil, the scrotal ulcer
healed. At 12 weeks, the peri-anal ulcer had also healed
completely.
Pathogenesis
The pathogenesis of nicorandil-induced ulceration is
unclear. Some have postulated a local effect of nicorandil
metabolites, as the drug is known to concentrate in the
saliva. This however, does not explain its association with
anal ulcers, as nicorandil is mainly excreted in urine. A
'vascular steal phenomenon' has also been proposed
although neither the pharynx nor the anus are areas of
vascular watershed [6]. Some authors have advocated a
dose-dependent relationship as most patients with nic-
orandil-induced ulcers are on a dose of at least 20 mg
twice a day [14-16] but the phenomenon has been
reported even with doses of 10 mg daily [20].
More recently, Trechot et al. [21] hypothesised that pro-
longed therapy with nicorandil may result in its metabo-
lites (nicotinamide and nicotinic acid) merging with and
saturating the endogenous pool of nicotinamide adenine
dinucleotide (NAD)/nicotinamide adenine diphosphate
(NADP). This accumulation is thought to allow nicotinic
acid to become abnormally distributed in areas such as
the mucosa or skin, leaving it susceptible to ulceration.
Conclusion
Despite uncertain knowledge of the mechanisms
involved, evidence for the association between nicorandil
and gastrointestinal tract ulceration is strong, with rapid
resolution after its withdrawal. Therefore, it is important
to consider nicorandil as part of the differential diagnosis
in patients with persistent or multiple ulcers and/or fistu-
lae of the gastrointestinal tract to avoid unnecessary surgi-
cal intervention amongst a group of high-risk patients.
Alteration of the nicorandil dose should be discussed with
the appropriate specialist to optimise control of anginal
symptoms in these patients.
Abbreviations
CT: computed tomography; NAD: nicotinamide adenine
dinucleotide; NADP: nicotinamide adenine diphosphate
Consent
Written informed consent was obtained from the patient
for publication of this case report. A copy of the written
consent is available for review by the Editor-in-Chief of
this journal.
Competing interests
The authors declare that they have no competing interests.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Journal of Medical Case Reports 2009, 3:119 http://www.jmedicalcasereports.com/content/3/1/119
Page 4 of 4
(page number not for citation purposes)
Authors' contributions
CG analysed and interpreted the patient data and SW con-
ducted the literature review. Both CG and SW wrote the
manuscript. The original idea was that of CB who super-
vised and edited the manuscript. All authors read and
approved the final manuscript.
References
1. Trends in Prescribing of and Spending on Nicorandil in Gen-
eral Practice in England   [http://www.nhsbsa.nhs.uk/Prescription
Services/Documents/NPC_Cardio_Dec_08.ppt]
2. Frampton J, Buckley MM, Fitton A: Nicorandil. A review of its
pharmacology and therapeutic efficacy in angina pectoris.
Drugs 1992, 44:625-655.
3. The Task Force on the Management of Stable Angina Pectoris of the
European Society of Cardiology: Guidelines on the management
of stable angina pectoris: executive summary.  Eur Heart J
2006, 27:1341-1381.
4. Nicorandil   [http://bnf.org/bnf/bnf/58/
27014.htm?q=%22nicorandil%22]
5. Reichert S, Antunes A, Tréchot P, Barbaud A, Weber M, Schmutz JL:
Major aphthous stomatitis induced by nicorandil.  Eur J Derma-
tol 1997, 7:132-133.
6. Watson A, Al-Ozairi O, Fraser A, Loudon M, O'Kelly T: Nicorandil
associated anal ulceration.  Lancet 2002, 360:546-547.
7. Toquero L, Briggs CD, Bassuini MM, Rochester JR: Anal ulceration
associated with Nicorandil: case series and review of the lit-
erature.  Colorectal Dis 2006, 8:717-720.
8. Ogden S, Mukasa Y, Lyon CC, Coulson IH: Nicorandil-induced
peristomal ulcers: is nicorandil also associated with gastroin-
testinal fistula formation?  Br J Dermatol 2007, 156:608-609.
9. King PM, Suttie SA, Jansen JO, Watson AJ: Perforation of the ter-
minal ileum: a possible complication of nicorandil therapy.
Surgeon 2004, 2:56-57.
10. Cotter CJ, Lowe T: Re: King PM, Suttie SA, Jansen JO, Watson
AJ. Perforation of the terminal ileum: a possible complica-
tion of nicorandil therapy. Surg J R Coll Surg Edinb Irel 2004, 1:
56-57.  Surgeon 2005, 3:119.
11. Kamath S, Kembrey K, Bhagwandas K: Perianal fistula, colorectal
surgery and nicorandil.  Clin Exp Dermatol 2008, 33:192-193.
12. Marquart-Elbaz C, Lipsker D, Grosshans E, Cribier B: Oral ulcers
induced by nicorandil: prevalence and clinicopathological
aspects.  Ann Dermatol Venereol 1999, 126:587-590.
13. Dunn N, Freemantle S, Pearce G, Wilton LV, Mann RD: Safety pro-
file of nicorandil--prescription-event monitoring (PEM)
study.  Pharmacoepidemiol Drug Saf 1999, 8:197-205.
14. Agbo-Godeau S, Joly P, Lauret P, Szpirglas R, Szpirglas H: Associa-
tion of major aphthous ulcers and nicorandil.  Lancet 1998,
352:1598-1599.
15. Healy CM, Smyth Y, Flint SR: Persistent nicorandil induced oral
ulceration.  Heart 2004, 90:e38.
16. Webster K, Godbold P: Nicorandil induced oral ulceration.  Br
Dent J 2005, 198:619-621.
17. Boulinguez S, Sommet A, Bédane C, Viraben R, Bonnetblanc JM: Oral
nicorandil-induced lesions are not aphthous ulcers.  J Oral
Pathol Med 2003, 32:482-485.
18. Drug Safety Update: Volume 1, Issue 11, June 2008: MHRA
[http://www.mhra.gov.uk/Publications/Safetyguidance/DrugSafetyUp
date/CON017928]
19. Cupples HE, McGahey DT: Dual pathology: cervicofacial actino-
mycosis and nicorandil-induced oral ulceration.  J Laryngol Otol
2007, 14:1-3.
20. Laveau F, Chapuis H, Dandurand M, Guillot B: Eosinophilic ulcera-
tion of the tongue.  Ann Dermatol Venereol 2000, 127:716-718.
21. Trechot P, Barbaud A, Petitpain N, Claeys A, Schmutz J-L: Nicoran-
dil and ulcerations: a NAD/NADP and nicotinic acid-depend-
ent side effect?  Br J Dermatol 2008, 158:1150.